AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36549740
Drug: Free access
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free access to a comprehensive list of essential medicines for 24 months
Trial: 36549786
Drug: Home-based inspiratory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based inspiratory muscle training (IMT) for 12 weeks, training twice daily using a threshold inspiratory muscle trainer
Trial: 36549898
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily, increased to 20 mg daily after 4 weeks if no toxicity
Trial: 36550428
Drug: Two additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two additional cycles of Lutathera® (7.4 GBq infusion each, separated by 8 weeks)
Trial: 36550428
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (active surveillance)
Trial: 36550466
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine refusal
Trial: 36550559
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL crystalloid fluid bolus (FB) administered over 30 min
Trial: 36550559
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL crystalloid fluid bolus (FB)
Trial: 36550562
Drug: Clazakizumab (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab (12.5 mg subcutaneous once every 4 weeks)
Trial: 36550683
Drug: Trastuzumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (8 mg/kg loading dose and then 6 mg/kg every 3 weeks) and Irinotecan (120 mg/m2 days 1 and 8 every 3 weeks)
Trial: 36551677
Drug: SAMITAL granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMITAL granules for oral suspension (20 mL, four times daily)
Trial: 36551677
Drug: SAMITAL granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMITAL granules for oral suspension
Trial: 36553294
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for SDB
Trial: 36553294
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for SDB
Trial: 36554581
Drug: Intravenous route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous route for postoperative pain management
Trial: 36554820
Drug: Short-term psychoanalytic
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychoanalytic therapy with Johanna (good outcome)
Trial: 36554820
Drug: Short-term psychoanalytic
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychoanalytic therapy with Sonja (poor outcome)
Trial: 36554860
Drug: Traditional form
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional form of therapy (Control)
Trial: 36555933
Drug: Placebo→Rituximab 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo→Rituximab 1000 mg
Trial: 36555933
Drug: Placebo→Rituximab 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo→Rituximab 500 mg
Trial: 36560966
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C pressurized intraperitoneal aerosolized chemotherapy (MMC-PIPAC) combined with systemic chemotherapy (FOLFIRI)
Trial: 36561174
Drug: Ivermectin 600
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 600 μg/kg daily for 6 days
Trial: 36561174
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 6 days
Trial: 36561714
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation (E-Stim) for 1 hour daily for up to 14 days on both gastrocnemius muscles (GNMs)
Trial: 36561723
Drug: Prior use
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior use of non-steroidal anti-inflammatory drugs
Trial: 36561857
Drug: Initial Medication
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial Medication Adherence (IMA) intervention
Trial: 36562136
Drug: MA (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA (160 mg oral daily)
Trial: 36562136
Drug: MA +
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MA + LNG-IUS (160 mg oral daily + LNG-IUS)
Trial: 36562609
Drug: Combined platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined platinum-based chemotherapy with cetuximab treatment
Trial: 36562831
Drug: Metformin arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin arm (n=15) - received letrozole 2.5 mg/day plus metformin (2000±500 mg/day)
Trial: 36562831
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (n=15) - received letrozole 2.5 mg/day
Trial: 36562831
Drug: Lean arm
RxNorm normalized name: Lophophytum leandrii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean arm (n=15) - received letrozole 2.5 mg/day
Trial: 36562873
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of elamipretide
Trial: 36563086
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TEST; 200 mg·wk -1)
Trial: 36564033
Drug: Higher urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher urinary lithium excretion
Trial: 36564099
Drug: Anetumab ravtansine
RxNorm normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anetumab ravtansine (6.5 mg/kg) and pegylated liposomal doxorubicin (30 mg/m2)
Trial: 36564099
Drug: Anetumab ravtansine
RxNorm normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anetumab ravtansine (6.5 mg/kg) and pegylated liposomal doxorubicin (30 mg/m2) in patients with high mesothelin expression
Trial: 36564123
Drug: placebo (switching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (switching to guselkumab 100 mg at week 24)
Trial: 36564123
Drug: non-biological standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-biological standard of care
Trial: 36564126
Drug: Intratumoral V937
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral V937 plus intravenous ipilimumab 3 mg/kg Q3W for four doses starting on day 22.
Trial: 36564274
Drug: AS37 adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS37 adjuvanted vaccine
Trial: 36564274
Drug: Licensed alum-adjuvanted
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed alum-adjuvanted meningococcal serogroup C (MenC-CRM) vaccine
Trial: 36564395
Drug: Milvexian (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (100 mg)
Trial: 36564395
Drug: Milvexian (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (100 mg) and Rifampin (600 mg)
Trial: 36564955
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) 5 g once daily for 12 weeks
Trial: 36565044
Drug: Conventional endodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional endodontic treatment (control group)
Trial: 36565044
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (PRP and conventional treatment)
Trial: 36566079
Drug: Lenacapavir (927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenacapavir (927 mg) subcutaneously every 26 weeks with oral daily emtricitabine (200 mg) and tenofovir alafenamide (25 mg) for 28 weeks, followed by subcutaneous lenacapavir (927 mg) plus oral daily tenofovir alafenamide (25 mg) (group 1)
Trial: 36566079
Drug: Lenacapavir (927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenacapavir (927 mg) subcutaneously every 26 weeks with oral daily emtricitabine (200 mg) and tenofovir alafenamide (25 mg) for 28 weeks, followed by subcutaneous lenacapavir (927 mg) plus oral daily bictegravir (75 mg) (group 2)
Trial: 36566079
Drug: Oral daily
RxNorm normalized name: Summer's Eve Sheer Floral Daily Cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily lenacapavir (600 mg on days 1 and 2, followed by 50 mg daily) with emtricitabine (200 mg) and tenofovir alafenamide (25 mg) (group 3)
Trial: 36566079
Drug: Oral daily
RxNorm normalized name: Summer's Eve Sheer Floral Daily Cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) (group 4)
Trial: 36566186
Drug: Postoperative albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative albumin infusion
Trial: 36566186
Drug: Postoperative albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative albumin infusion in patients with preoperative albumin level < 40 g/L
Trial: 36566186
Drug: Postoperative albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative albumin infusion in patients with duration of surgery ≥ 3 h
Trial: 36566202
Drug: DDEA 2.32%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDEA 2.32% gel applied twice daily (BID)
Trial: 36566202
Drug: DDEA 1.16%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDEA 1.16% gel applied four times daily (QID)
Trial: 36566266
Drug: BRAF-MEK inhibitors
RxNorm normalized name: Mitogen-activated protein kinase (MEK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRAF-MEK inhibitors
Trial: 36566266
Drug: Advanced melanoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced melanoma stage, melanoma systemic therapies
Trial: 36566274
Drug: Oral GABA
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GABA twice-daily (n=41)
Trial: 36566274
Drug: Oral GABA
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GABA plus two-doses GAD-alum (n=25)
Trial: 36566344
Drug: AK111 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK111 75 mg
Trial: 36566344
Drug: AK111 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK111 150 mg
Trial: 36566344
Drug: AK111 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK111 300 mg
Trial: 36566344
Drug: AK111 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK111 450 mg
Trial: 36567076
Drug: e-RPT (web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-RPT (web-based relapse prevention therapy)
Trial: 36567076
Drug: face-to-face RPT
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: face-to-face RPT (traditional relapse prevention therapy)
Trial: 36567211
Drug: Post-TCR treatments
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-TCR treatments (carfilzomib, pomalidomide, daratumumab); median treatment duration 3.3 months
Trial: 36567211
Drug: Post-TCR treatments
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-TCR treatments (carfilzomib, pomalidomide, daratumumab)
Trial: 36568239
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 1200 mg every 2 weeks intravenously until disease progression, unacceptable toxicity, or withdrawal.
Trial: 36568250
Drug: Azacitidine (75mg/m2/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (75mg/m2/d on days 1-5 subcutaneous) combined with Homoharringtonine (HHT 2mg/m2/d on days 4-8 intravenous over 3 hours), Idarubicin (6mg/m2/d on days 4-6 intravenous), and Cytarabine (100mg/m2/d on days 4-10 intravenous)
Trial: 36568414
Drug: Intravenous ACBMNC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ACBMNC infusion (targeted at 5 × 10^7 cells)
Trial: 36568559
Drug: Non-albuminuric CKD
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-albuminuric CKD with eGFR <45 mL/min/1.73 m²
Trial: 36568559
Drug: Non-albuminuric CKD
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-albuminuric CKD with eGFR ≥60 mL/min/1.73 m²
Trial: 36568789
Drug: WISER intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WISER intervention (Web-based Implementation for the Science of Enhancing Resilience), delivered daily for 10 days.
Trial: 36569610
Drug: Short-course (SC)
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course (SC) antidepressant therapy
Trial: 36569610
Drug: Long-course (LC)
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course (LC) antidepressant therapy
Trial: 36569610
Drug: 2-week FM
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week FM therapy
Trial: 36569610
Drug: 4-week FM
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week FM therapy
Trial: 36569905
Drug: AK104 (PD-1/CTLA-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK104 (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy (mXELOX)
Trial: 36569905
Drug: AK104 (PD-1/CTLA-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK104 (PD-1/CTLA-4 bispecific antibody) combined with single-drug capecitabine therapy
Trial: 36569905
Drug: Steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid therapy combined with mycophenolate mofetil
Trial: 36569905
Drug: AK104 rechallenged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK104 rechallenged after hormone therapy
Trial: 36570150
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet supplemented with probiotics (10 unspecified dosage)
Trial: 36570498
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Training (HIIT) 3 times a week + Treatment as Usual (TAU)
Trial: 36570649
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg once daily for 3 months
Trial: 36571164
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) for patients with underlying ICAD
Trial: 36571164
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) for patients without underlying ICAD
Trial: 36571171
Drug: Combined chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chlorpheniramine 10 mg and ranitidine 50 mg
Trial: 36571611
Drug: Topical cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cetirizine with minoxidil
Trial: 36571611
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil with placebo
Trial: 36571770
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 1200 mg intravenously every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal.
Trial: 36571826
Drug: Cold therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold therapy applied 10 minutes before port needle removal
Trial: 36572501
Drug: Low-dose chest
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chest CT scan
Trial: 36572571
Drug: Capivasertib 400
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib 400 mg (orally, twice daily, with an intermittent schedule of 4 days on, 3 days off) plus abiraterone acetate 1000 mg (orally administered once daily) and prednisone 5 mg (twice daily)
Trial: 36573071
Drug: Smiling is
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smiling is Fun (internet-based treatment)
Trial: 36573071
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control phase)
Trial: 36573651
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (racemic ketamine hydrochloride) administered over a 40-minute intravenous infusion, 2 times per week on nonconsecutive days for 4 weeks (8 sessions)
Trial: 36573717
Drug: High-dose glimepiride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glimepiride (2-4 mg/day)
Trial: 36574256
Drug: 3-pronged COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-pronged COVID-19 vaccine messaging platform (4-minute video, 1-page flyer, scripted message from ED staff)
Trial: 36574256
Drug: 3-pronged COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-pronged COVID-19 vaccine messaging platform
Trial: 36574387
Drug: LNG/EE TDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE TDS (delivering LNG 120 μg/day and EE 30 μg/day) for 12 weeks
Trial: 36574434
Drug: Rapid glucose
RxNorm normalized name: Clotam Rapid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid glucose infusion (3 times 20 grams of glucose i.v. over 5 minutes)
Trial: 36574434
Drug: Continuous glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose infusion (60 grams of glucose continuously over 3 hours)
Trial: 36574590
Drug: Tolvaptan 15
RxNorm normalized name: tolvaptan 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 15 mg daily
Trial: 39546129
Drug: 0.75% ruxolitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ruxolitinib cream
Trial: 36574595
Drug: vehicle to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle to 0.75% ruxolitinib cream
Trial: 36574595
Drug: vehicle to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle to 1.5% ruxolitinib cream
Trial: 36574595
Drug: ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ruxolitinib cream (both strengths)
Trial: 36574828
Drug: Ambezim-G (trypsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambezim-G (trypsin 5mg-chymotrypsin 5 mg)
Trial: 36574828
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ibuprofen and trypsin-chymotrypsin
Trial: 36575175
Drug: Inhalation technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation technique observation
Trial: 36575175
Drug: In-person observation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person observation of inhalation technique
Trial: 36575361
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus 8 Gy single fraction radiation therapy (RT)
Trial: 36575390
Drug: Ultrasound-guided SHPN
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided SHPN using 3 ml 5% bupivacaine plus 20 ml 10% phenol
Trial: 36575390
Drug: Fluoroscopic-guided SHPN
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopic-guided SHPN using 3 ml 5% bupivacaine plus 20 ml 10% phenol
Trial: 36575394
Drug: Prior paracetamol
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior paracetamol intake
Trial: 36575394
Drug: No prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prior paracetamol intake